You just read:

Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19 Infection and Associated Lung Complications

News provided by

Mallinckrodt Pharmaceuticals

Apr 01, 2020, 06:45 ET